



MEDIA ADVISORY

August 24, 2014

Sequella Presents Four Scientific Posters in September at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC

Rockville, Md. -- Sequella, Inc., a privately-held clinical stage anti-infectives company focused on commercializing novel treatments for antibiotic-resistant infectious diseases today announced it has been selected to present four posters at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September.

ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With 50% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field's foremost leaders to discuss the state of infection control and prevention on a global scale. The Conference will be held at the Walter E. Washington Convention Center in Washington, DC. All poster sessions will take place in Exhibit Hall B.

The September 6th poster session entitled: *Agents Targeting Clostridium difficile* (12 noon to 2:00 PM) will feature the following three posters related to Sequella's new lead drug for this indication, SQ641:

Promising activity of capuramycins against Clostridium difficile: E. Bogatcheva, M. Lemon, E. Kuenster, V.M. Reddy, G. Kolling, C.A. Nancy, L. Einck, M. Protopopova. Presentation Number: F-239

Capuramycin Derivative SQ641 as a New Promising Lead for Treatment of Clostridium Difficile Infection: M. Protopopova, E Bogatcheva, B. Nikonenko, M. Lemmon, V.M. Reddy, A. Gonzalez, R. Guerrant, C. Warren, G. Kolling, C.A. Nancy, L. Einck. Presentation Number: F-249

Treatment of Clostridium difficile Infection using SQ641, a Capuramycin Analogue, Increases Survival, Decreases Relapse and Improves Clinical Measures of Disease in a Murine Model: J.H. Moore, E.J. Van Opstal, G.L. Kolling, E. Bogatcheva, B. Nikonenko, L. Einck, R.L. Guerrant, M. Protopopova, C.A. Warren. Presentation Number: F-246

During the September 8th poster session entitled *Therapies for Mycobacteria Infections* (11:00 AM to 1:00 PM), Sequella will present its fourth poster:

Clinical Drug Candidate SQ109 in Combination with Second-Line Antituberculars: M. Protopopova, B. Nikonenko, V.M. Reddy, A. Gonzalez, L. Einck, and C.A. Nancy. Presentation Number: F-1629

About Sequella

Sequella is a privately-held clinical stage anti-infectives company focused on commercializing novel treatments for antibiotic-resistant infectious diseases. The company has been in operation for 17 years and has drugs in Phase 2 clinical trials for gastritis (*Helicobacter pylori*) and TB (Phase 2) and in IND-directed preclinical development for *Clostridium difficile* infections. Sequella leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity. www.sequella.com